Contemporary Use of Neuromuscular Blockade in Complex Patients

PROGRAM DESCRIPTION Critically ill patients may receive neuromuscular blocking agents (NMBAs) as adjunctive therapy in acute respiratory distress syndrome, shivering management, or for selected procedures; however, the use is less ...

PROGRAM DESCRIPTION
Critically ill patients may receive neuromuscular blocking agents (NMBAs) as adjunctive therapy in acute respiratory distress syndrome, shivering management, or for selected procedures; however, the use is less frequent than in the past. In addition, post-operative patients may experience residual blockade upon direct admission to the surgical intensive care unit (ICU). Awareness of the risks and management of NMBAs is important for ICU practitioners. Many aspects of patient management during continuous paralysis were addressed in the 2016 Society of Critical Care Medicine (SCCM) Guidelines for Sustained Neuromuscular Blockade; however, the use of a reversal agent was not included. This symposium will review the guidelines and discuss the role of NMBA reversal.

EDUCATIONAL OBJECTIVES
At the conclusion of this application-based educational activity, participants should be able to:Review key clinical practice statements from the 2016 Society of Critical Care Medicine (SCCM) Clinical Practice Guidelines for Sustained Neuromuscular Blockade in Critically Ill Adults.Apply the guidelines in patient case scenarios examining commonly administered neuromuscular blocking agents, their purpose, and potential side effects.Discuss strategies to minimize patient risk from residual neuromuscular blockade.

---

Write the first review

Resource tags